PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism
Inari Medical, Inc. (NARI)
Company Research
Source: GlobeNewswire
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed thrombolytics (CDT). The results were presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and Co-Global Principal Investigator (PI), during the Late-Breaking Clinical Trial Session at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. In recognition of the clinical relevance of the study, results were also simultaneously published in Circulation, the premier peer-reviewed journal of the American Heart Association (AHA). PEERLESS met its primary composite endpoint (win ratio 5.01, p “These results are crucial to guiding optimal PE tr
Show less
Read more
Impact Snapshot
Event Time:
NARI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NARI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NARI alerts
High impacting Inari Medical, Inc. news events
Weekly update
A roundup of the hottest topics
NARI
News
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Truist Financial Co. from $46.00 to $50.00. They now have a "hold" rating on the stock.MarketBeat
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $71.00 to $74.00. They now have a "buy" rating on the stock.MarketBeat
- Inari Medical, Inc. (NASDAQ: NARI) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Piper Sandler from $50.00 to $52.00. They now have a "neutral" rating on the stock.MarketBeat
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Robert W. Baird from $66.00 to $67.00. They now have an "outperform" rating on the stock.MarketBeat
NARI
Earnings
- 10/28/24 - Miss
NARI
Sec Filings
- 10/31/24 - Form 4
- 10/31/24 - Form 4
- 10/29/24 - Form 144
- NARI's page on the SEC website